RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
RELMADA THERAPEUTICS, INC. (RLMD), a Nevada corporation, filed this Current Report on Form 8-K on March 19, 2026. The filing announces a corporate update and reports financial results for the fiscal year ended December 31, 2025. The company is listed on the NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document states that the complete audited financial statements for the years ended December 31, 2025, and 2024, will be contained in the Annual Report on Form 10-K to be filed subsequently.
Material Changes
No specific material changes in financial metrics or operations are detailed in this filing text. The report serves as a notification that results have been issued and a conference call was conducted on March 19, 2026, to discuss the update.
Guidance, Outlook, and Risks
The filing references a corporate presentation (Exhibit 99.2) and a press release (Exhibit 99.1) for details on the corporate update and results. No specific guidance, outlook, risks, or contingencies are explicitly described within the text of this Form 8-K. The information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific financial results for the fiscal year ended December 31, 2025, in the upcoming Form 10-K filing.
- Review the press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2) referenced in this filing for detailed operational updates.
- Confirm the company's cash position and burn rate, as these figures are not included in this summary document.
- Monitor the conference call transcript for management commentary on future milestones and capital requirements.